Considering modern antibody production techniques, which evaluation best compares hybridoma-based monoclonal antibody production to recombinant antibody expression systems when prioritizing rapid humanization and large-scale clinical manufacture?

Recombinant expression is only useful for small research batches and cannot be scaled to clinical manufacture under any circumstances; hybridomas are the exclusive route for any production exceeding milligram quantities.

Recombinant expression systems offer greater flexibility for humanization, sequence modification, and scalable production in industrial bioreactors, while hybridomas are reliable for initial discovery but can be more cumbersome to humanize and scale clinically.

Hybridoma-based production is always superior in every respect, including speed of humanization and scalability to global clinical needs, and therefore recombinant methods offer no practical advantages whatsoever.

Both approaches are equivalent because hybridoma cells contain recombinant plasmids that automatically convert any mouse sequence into a human one during culture, eliminating any differences between methods.